NephroGenex Inc (NRX) is Resumed by Rodman & Renshaw to Neutral

NephroGenex Inc (NRX) was Resumed by Rodman & Renshaw to “Neutral”. Rodman & Renshaw advised their investors in a research report released on Apr 15, 2016.

Many Wall Street Analysts have commented on NephroGenex Inc. NephroGenex Inc was Downgraded by H.C. Wainwright to ” Neutral” on Apr 8, 2016.

NephroGenex Inc closed down -0.0156 points or -3.31% at $0.4551 with 23,785 shares getting traded on Monday. Post opening the session at $0.48, the shares hit an intraday low of $0.4551 and an intraday high of $0.49 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

NephroGenex Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company is engaged in the development of Pyridorin (pyridoxamine dihydrochloride). Pyridorin targets the pathogenic oxidative chemistries that emerge in diabetic patients and lead to kidney disease. The Company’s product pipeline includes oral Pyridorin and intravenous (I.V.) Pyridorin. Oral Pyridorin is under development as a treatment for slowing the progression of diabetic nephropathy due to type 2 diabetes. I.V. formulation of Pyridorin is under development for the treatment of specific types of acute kidney injury (AKI). Pyridorin has received Fast Track Designation from the United States Food and Drug Administration (FDA) for the treatment of Diabetic Nephropathy.

NephroGenex Inc

Leave a Reply

NephroGenex Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on NephroGenex Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.